PEDIATRIC SURGERY *Update**
Volume 63 No. 02 AUGUST 2024

Probiotics for NEC

Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease primarily affecting preterm infants, characterized by intestinal inflammation and necrosis, which leads to significant morbidity and mortality. The exploration of probiotics as a preventative measure against NEC has gained substantial attention due to their potential benefits in enhancing intestinal health and reducing disease incidence. Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. These benefits are mediated through several mechanisms, including the enhancement of the intestinal barrier, production of short-chain fatty acids such as butyrate, competition with pathogenic bacteria, and modulation of the immune system by downregulating pro-inflammatory genes and upregulating cytoprotective genes.

The routine use of probiotics in preterm infants began gaining traction in the late 1990s. A seminal study by Dr. Angela Hoyos in 1999 highlighted that daily administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in a neonatal intensive care unit significantly reduced the incidence of NEC and associated mortality. This pioneering research paved the way for numerous clinical trials and studies that followed, involving over 10,000 preterm infants, to evaluate the efficacy of probiotics in preventing NEC. The general consensus from these studies supports the beneficial role of probiotics in reducing the risk of NEC, mortality, and late-onset sepsis.

Randomized controlled trials (RCTs) have provided substantial evidence on the effectiveness of probiotics in preventing NEC. For example, Bin-Nun et al. conducted an RCT in 2005 which demonstrated that a mixture of B. infantis, S. thermophilus, and B. bifidus significantly reduced the incidence of NEC. Similarly, Dani et al. found in their 2013 study that supplementation with Lactobacillus rhamnosus GG (LGG) led to a reduction in NEC among preterm infants. Another notable trial, the ProPrems Trial conducted in Australia and New Zealand, involved very low birth weight infants, and found that supplementation with a combination of B. infantis, S. thermophilus, and B. lactis reduced the incidence of NEC by over half. Despite some heterogeneity in trial designs and probiotic strains used, systematic reviews and meta-analyses have consistently shown that probiotic supplementation favors the prevention of NEC, mortality, and late-onset sepsis.

Observational studies further support the findings from RCTs. A comprehensive review of 30 non-randomized studies involving over 77,000 infants from 18 different countries reported that probiotic supplementation significantly reduced the risk of NEC. This body of evidence underscores the potential of probiotics as a preventative strategy against NEC in preterm infants.

Several professional societies have issued recommendations regarding the use of probiotics in preterm infants, reflecting the growing acceptance and cautious optimism within the medical community. The Canadian Pediatric Society (CPS) advises caution and suggests considering probiotics for preterm infants at risk for NEC, particularly those with birth weights over 1 kilogram. The European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) emphasizes that probiotics should be produced under stringent manufacturing practices and that clinicians should discuss potential risks and benefits with parents. In contrast, the American Academy of Pediatrics (AAP) does not recommend universal probiotic administration for preterm infants, citing concerns about safety, particularly the lack of FDA-approved products and the potential risk of probiotic-associated sepsis.

The implementation of probiotics in clinical practice varies widely across different regions and institutions. For instance, Sunnybrook Health Sciences Centre in Canada reported a decrease in NEC rates from 4.4% to 1.7% after implementing probiotic supplementation with Lactobacillus reuteri DSM 17938. Similarly, Oregon Health & Science University in the United States observed a reduction in NEC incidence from 11% to 2.7% with the use of B. infantis EVC001. The University of Utah Medical Center also reported a decrease in NEC rates from 7% to 2% with their probiotic protocol, which included multiple strains of Bifidobacteria and Lactobacillus. Emory University Midtown in the United States saw a reduction in NEC incidence from 13.2% to 5.6% after implementing a regimen involving Lactobacillus reuteri.

Despite the promising results, there are safety concerns associated with probiotic use, particularly regarding the risk of contamination and probiotic-associated sepsis. Cases of sepsis linked to probiotics have been reported, underscoring the importance of stringent safety protocols and high-quality manufacturing practices. It is crucial for facilities implementing probiotic supplementation to develop comprehensive guidelines to ensure safety and to monitor the effects of this therapy closely.

In conclusion, the use of probiotics to prevent NEC in preterm infants has been extensively studied and generally supported by clinical evidence. While more clinical trials may not significantly alter the pooled outcomes given the existing body of research, the decision to implement routine probiotic supplementation remains complex and multifaceted. Factors such as a center's baseline NEC incidence, the quality of the probiotic products available, and the effectiveness of other preventive measures, like promoting a human milk diet, play critical roles in this decision. Engaging multiple stakeholders, including families, in the decision-making process is essential to ensure informed choices and optimize outcomes for preterm infants. Although concerns about product quality and safety persist, the substantial evidence supporting the benefits of probiotics suggests that their use can be a valuable strategy in the fight against NEC, particularly in high-risk populations.

References:

1- Barbian ME, Patel RM: Probiotics for prevention of necrotizing enterocolitis: Where do we stand? Semin

Perinatol. 47(1):151689, 2023
2- Patel RM, Underwood MA. Probiotics and necrotizing enterocolitis. Semin Pediatr Surg. 27(1):39-46, 2018
3- Beghetti I, Panizza D, Lenzi J, Gori D, Martini S, Corvaglia L, Aceti A: Probiotics for Preventing Necrotizing Enterocolitis in Preterm Infants: A Network Meta-Analysis. Nutrients. 13(1):192, 2021
4- Underwood MA. Probiotics and the prevention of necrotizing enterocolitis. J Pediatr Surg. 54(3):405-412, 2019
5- Nolan LS, Rimer JM, Good M. The Role of Human Milk Oligosaccharides and Probiotics on the Neonatal Microbiome and Risk of Necrotizing Enterocolitis: A Narrative Review. Nutrients. 12(10):3052, 2020
6- Underwood MA. Impact of probiotics on necrotizing enterocolitis. Semin Perinatol. 41(1):41-51, 2017

Hepatoblastoma

Hepatoblastoma (HB) is the most common primary liver malignancy in children, predominantly affecting those under three years of age. Over the past few decades, the overall survival rates have significantly improved from 30% to approximately 80%, thanks to advancements in chemotherapy and surgical techniques, including liver transplantation (LT). The disease stage and current treatment protocols are heavily influenced by the extent of the tumor, assessed using the PRETEXT (pre-treatment extent of disease) and POST-TEXT (post-treatment extent of disease) systems, which help in determining the surgical resectability and the need for LT.

Innovations in chemotherapy, particularly with cisplatin-based regimens, have rendered many initially unresectable tumors resectable. However, the curability of chemotherapy-resistant or metastatic HB relies heavily on achieving radical surgical resection. Recent studies indicate that aggressive surgical management of lung metastases, which are common in HB, can lead to favorable prognoses even when complete remission is not achieved through chemotherapy alone.

Preoperative imaging technologies have advanced considerably, with 3D imaging and virtual simulation of hepatectomy providing detailed insights into the anatomical relationships between tumors and vascular structures. These technologies, including 3D printing, have not only enhanced surgical planning but also improved patient and parent education. Additionally, diffusion-weighted MRI and the use of hepatobiliary MRI contrast agents like gadoxetate disodium have proven effective in detecting satellite lesions and evaluating the relationship of tumors to critical vascular structures.

Intraoperatively, augmented reality navigation systems and indocyanine green (ICG) fluorescence imaging have improved the precision of tumor localization and resection. ICG, in particular, has shown high sensitivity in identifying liver tumors during surgery, although it has limitations in detecting tumors deeper than 10 mm from the organ surface.

Minimally invasive surgical approaches, such as laparoscopic and robotic-assisted liver resections, have been increasingly applied in pediatric HB cases. These techniques, when performed by experienced surgeons, offer reduced postoperative complications and shorter recovery times. The use of radiofrequency-assisted pre-coagulation and advanced hemostatic techniques has further enhanced the safety and efficacy of these minimally invasive procedures.

The associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure has emerged as a valuable technique for increasing the future liver remnant (FLR) in patients with extensive liver tumors. Although initially associated with high morbidity, modified ALPPS procedures have shown promising results in selected pediatric HB cases, facilitating successful resections that might otherwise necessitate LT.

Liver transplantation remains a critical option for patients with unresectable HB. Primary LT is often recommended for advanced HB cases, especially those classified as central POST-TEXT III or IV. Advances in perioperative care and surgical techniques have significantly improved the outcomes of LT, with five-year survival rates now approaching 90%. Living donor liver transplantation (LDLT) offers a valuable alternative, particularly in regions with organ shortages, allowing for optimal timing and reduced delays in treatment.

Management of metastatic HB, particularly lung metastases, continues to be challenging. Neoadjuvant chemotherapy has been effective in achieving complete remission of lung metastases in over 50% of cases. For residual or recurrent metastatic lesions, surgical resection remains a critical component of treatment. Techniques such as ICG navigation surgery and CT-guided localization have enhanced the precision of metastasectomy, contributing to improved outcomes.

Relapse in HB patients, although less common with modern treatment protocols, still poses a significant challenge. Factors such as age, PRETEXT stage, and initial metastatic status are important predictors of recurrence. Despite this, a substantial proportion of relapsed patients can achieve long-term survival through repeat surgical interventions and chemotherapy. The feasibility of re-transplantation in selected cases of intragraft recurrence further underscores the importance of achieving complete tumor resection whenever possible.

In conclusion, the management of hepatoblastoma has seen remarkable advancements over the years, with significant improvements in imaging, surgical techniques, and transplantation strategies. Continued research and technological innovation hold promise for further improving the prognosis and quality of life for children affected by this malignancy. Integrating these advancements into a comprehensive, multidisciplinary approach remains key to optimizing outcomes and achieving long-term remission for hepatoblastoma patients.

References:

1- Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL: Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 26(1):19-28, 2014

2- Sharma D, Subbarao G, Saxena R: Hepatoblastoma. Semin Diagn Pathol. 34(2):192-200, 2017

3- Lake CM, Tiao GM, Bondoc AJ: Surgical management of locally-advanced and metastatic hepatoblastoma. Semin Pediatr Surg. 28(6):150856, 2019

4- Ziogas IA, Benedetti DJ, Wu WK, Matsuoka LK, Izzy M, Rauf MA, Pai AK, Bailey CE, Alexopoulos SP: Management of hepatoblastoma in the United States: Can we do better? Surgery. 170(2):579-586, 2021

5- Wu PV, Rangaswami A: Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy. Curr Oncol Rep. 24(9):1209-1218, 2022

6- Honda M, Uchida K, Irie T, Hirukawa K, Kadohisa M, Shimata K, Isono K, Shimojima N, Sugawara Y, Hibi

T: Recent advances in surgical strategies and liver transplantation for hepatoblastoma. Cancer Med. 12(4):3909-3918, 2023
7- Murawski M, Weeda VB, Czauderna P. Surgical management in hepatoblastoma: points to take. Pediatr Surg Int. 39(1):81, 2023

Artificial Intelligence in Pediatric Surgery

The integration of artificial intelligence (AI) into pediatric surgery is rapidly evolving, bringing about significant transformations in healthcare. Artificial intelligence, defined as the capability of a machine to imitate intelligent human behavior, is making remarkable strides in the medical field. In pediatric surgery, AI's applications range from diagnostics to intraoperative assistance and postoperative care.

One of the critical areas where AI has shown significant potential is in the diagnosis of acute appendicitis in children. Acute appendicitis is the most common pediatric surgical emergency worldwide, and early diagnosis is crucial to prevent complications such as perforation and peritonitis. Traditional diagnostic methods rely on clinical signs, laboratory tests, and imaging, which can be subjective and variable in accuracy. AI algorithms, however, can analyze a combination of clinical, laboratory, and imaging data to provide more accurate and consistent diagnoses. For instance, a systematic review found that AI models achieved diagnostic accuracy rates above 90%, highlighting their potential to outperform traditional diagnostic methods.

AI's role extends into the operating room, where it assists surgeons with real-time data and procedural guidance. Technologies like augmented reality (AR) and machine learning algorithms are increasingly being integrated into surgical procedures. AR can overlay critical information onto the surgeon's field of view, enhancing precision and reducing errors. Machine learning models can analyze electro-neurophysiological data to distinguish between different tissue types during complex surgeries like selective dorsal rhizotomy, thereby improving outcomes.

Postoperative care is another area where AI can make a substantial impact. AI algorithms can predict postoperative complications by analyzing patient data, enabling early interventions and personalized care plans. This predictive capability is particularly valuable in pediatric patients, who may have different physiological responses compared to adults. AI-driven predictive analytics can optimize recovery strategies, reduce hospital stays, and improve overall patient outcomes.

While the benefits of AI in pediatric surgery are substantial, they come with a host of ethical, legal, and societal challenges. These challenges must be addressed to ensure that AI technologies are used responsibly and equitably. One of the primary ethical concerns with AI in healthcare is the potential for algorithmic bias. AI systems learn from historical data, which may contain biases that can be perpetuated or even amplified by the algorithms. This is particularly concerning in pediatric surgery, where biased algorithms could disproportionately affect vulnerable populations. Ensuring fairness and transparency in AI algorithms is critical to prevent discriminatory outcomes.

Patient privacy is another significant concern. AI systems require large amounts of data to function effectively, raising questions about data security and patient consent. Robust safeguards must be implemented to protect patient data and ensure that it is used ethically and transparently.

The legal implications of AI in pediatric surgery revolve around accountability and liability. When AI systems are used in clinical decision-making, it becomes challenging to determine who is responsible for errors the machine, the developer, or the healthcare provider. Clear guidelines and regulations are needed to define accountability and ensure that patients have recourse in case of malpractice.

From a societal perspective, the deployment of AI in healthcare must transcend socio-economic boundaries to ensure equitable access to these advanced technologies. This involves not only making the technology available but also providing the necessary training and education to healthcare providers to use AI tools effectively.

For AI to be successfully integrated into pediatric surgery, it is essential to build trust among healthcare providers, patients, and their families. This involves transparent communication about how AI systems work, their benefits, and their limitations. Education and training programs for healthcare professionals are crucial to ensure they are well-equipped to leverage AI technologies effectively and ethically.

Artificial intelligence is poised to revolutionize pediatric surgery by enhancing diagnostic accuracy, improving surgical precision, and optimizing postoperative care. However, the successful integration of AI into pediatric healthcare requires addressing ethical, legal, and societal challenges. Ensuring fairness, transparency, and patient privacy, while establishing clear accountability frameworks and providing comprehensive education and training, are essential steps towards harnessing the full potential of AI in pediatric surgery. As we navigate this transformative era, the continuous evolution of AI holds the promise of a future where technology becomes an indispensable ally in delivering optimal pediatric care.

References:

1- Cobianchi L, Verde JM, Loftus TJ, Piccolo D, Dal Mas F, Mascagni P, Garcia Vazquez A, Ansaloni L, Marseglia GR, Massaro M, Gallix B, Padoy N, Peter A, Kaafarani HM. Artificial Intelligence and Surgery: Ethical Dilemmas and Open Issues. J Am Coll Surg. 235(2):268-275, 2022

2- Yang Y, Zhang Y, Li Y. Artificial intelligence applications in pediatric oncology diagnosis. Explor Target Antitumor Ther. 4(1):157-169, 2023

3- Loftus TJ, Altieri MS, Balch JA, Abbott KL, Choi J, Marwaha JS, Hashimoto DA, Brat GA, Raftopoulos Y, Evans HL, Jackson GP, Walsh DS, Tignanelli CJ. Artificial Intelligence-enabled Decision Support in Surgery: State-of-the-art and Future Directions. Ann Surg. 278(1):51-58, 2023

4- Tsai AY, Carter SR, Greene AC. Artificial intelligence in pediatric surgery. Semin Pediatr Surg. 33(1):151390, 2024

5- Rey R, Gualtieri R, La Scala G, Posfay Barbe K. Artificial Intelligence in the Diagnosis and Management of Appendicitis in Pediatric Departments: A Systematic Review. Eur J Pediatr Surg. doi: 10.1055/a-2257-512, 2024
6- Verhoeven R, Hulscher JBF. Editorial: Artificial intelligence and machine learning in pediatric surgery. Front Pediatr. 12:1404600, 2024
7- Elahmedi M, Sawhney R, Guadagno E, Botelho F, Poenaru D. The State of Artificial Intelligence in Pediatric Surgery: A Systematic Review. J Pediatr Surg. 59(5):774-782, 2024

***Edited by: Humberto Lugo-Vicente, MD, FACS, FAAP**
Professor of Pediatric Surgery, UPR - School of Medicine, UCC School of Medicine & Ponce School of Medicine.
Pediatric Surgery, San Jorge Children's & Woman Hospital.
Postal Address: P.O. Box 10426, San Juan, Puerto Rico USA 00922-0426.
Tel (787) 340-1868 E-mail: *pediatricsurgerypr@gmail.net*
Internet: pedsurgeryupdate.com

**** PSU 1993-2024***
ISSN 1089-7739